1.媒体来源:
外媒 sciencealert
2.记者署名:
David Nield
3.完整新闻标题:
Viagra May Be One of Our Best Existing Options For an Alzheimer's Treatment
Health
威而钢可能是我们目前治疗阿兹海默症最好的选择之一
4.完整新闻内文:
Viagra May Be One of Our Best Existing Options For an Alzheimer's Treatment
Health
03 March 2026
By David Nield
Repurposing treatments to treat multiple conditions is quicker, safer, and
less expensive than developing new ways to manage health.
A recent ranking of existing drugs and vaccines has nominated the erectile
dysfunction treatment marketed under the brand name of Viagra as one of our
best options to protect individuals against Alzheimer's disease.
威而钢可能是我们目前治疗阿兹海默症最好的选择之一
健康
2026年3月3日
经过大卫·尼尔德
重新利用现有疗法来治疗多种疾病比开发新的健康管理方法更快、更安全、更便宜。
最近一项针对现有药物和疫苗的排名将以“威而钢”为品牌名销售的治疗勃起功能障碍的
药物列为 保护人们免受阿兹海默症侵害的最佳选择之一。
This review comes from a panel of 21 experts who combed through anonymous
nominations, clinical evidence, and lay advice, settling on a list of 80
candidates that show potential in treating the neurodegenerative disorder.
Of those candidates, three ultimately stood out: Sildenafil (Viagra),
Zostavax (a shingles vaccine), and riluzole (a drug used to treat amyotrophic
lateral sclerosis).
本次评选由 21 位专家组成的小组进行，他们仔细审查了匿名提名、临床证据和普通民众
的建议，最终确定了 80 个在治疗这种神经退化性疾病方面具有潜力的候选药物。
在这些候选药物中，最终有三种脱颖而出： 西地那非（威而钢）、带状疱疹疫苗（
Zostavax）和利鲁唑（一种用于治疗肌萎缩侧索硬化症的药物）。
https://www.sciencealert.com/images/2026/02/ViagraPill.jpg
Viagra pill bottle
Viagra may be useful for more than just erectile dysfunction. (David
Trinks/Unsplash)
威而钢的用途可能不仅限于治疗勃起功能障碍。 （图片来源：David Trinks/Unsplash）
These treatments have all been linked to Alzheimer's prevention by previous
studies, but the fact that they've been selected by experts as most suitable
for future development is a notable endorsement of their potential.
The review used what's known as a Delphi consensus – a structured process
often used in medicine and public health to help groups arrive at decisions
that everyone can get behind.
先前的研究已经证实这些疗法与预防阿兹海默症有关，但专家们选择它们作为最适合未来
发展的疗法，这无疑是对其潜力的显著认可。
这项审查采用了所谓的德尔菲共识法—一种结构化的流程，常用于医学和公共卫生领域
，以帮助团体达成每个人都能支持的决策。
"Each of the priority candidates has evidence supporting relevant underlying
mechanisms of action, non-clinical studies, and clinical evidence from
epidemiological studies and/or preliminary clinical trials," write the
researchers in their published paper.
"The tolerability of each of these compounds is also suitable for
administration to a frailer population of older individuals as part of a
well-monitored clinical trial program. We therefore recommend each of these
therapeutic approaches as a high priority for clinical trials for the
treatment or prevention of Alzheimer's disease."
研究人员在发表的论文中写道： “每个优先候选药物都有证据支持相关的潜在作用机制
、非临床研究以及流行病学研究和/或初步 临床试验的临床证据。”
“这些化合物的耐受性均良好，适合在严密监测的 临床试验项目中用于体弱多病的年长
人群。因此，我们建议将这些治疗方法作为治疗或预防阿兹海默症临床试验的优先选择
。”
Sildanefil is an inhibitor that relaxes blood vessels, commonly used to
promote erections. Past studies have shown how it can also cut Alzheimer's
risk, reducing the toxic accumulation of the tau protein so common in the
brains of people with Alzheimer's.
The Zostavax shingles vaccine is even more promising than Sildanefil, the
panel concluded. Though the relationship isn't fully understood, past studies
suggest the vaccine boosts the immune system to protect against Alzheimer's.
Lastly, there's riluzole, a drug that prevents neurons from dying by altering
biological pathways and reducing levels of brain chemicals previously
associated with neurodegenerative diseases like Alzheimer's.
西地那非是一种血管舒张抑制剂，常用于促进勃起。过去的研究表明，它还可以降低阿兹
海默症的风险，减少阿兹海默症患者大脑中常见的蛋白的毒性累积。
专家小组总结道，带状疱疹疫苗Zostavax比西地那非更有前景。虽然其作用机制尚未完全
明了，但过去的研究表明，该疫苗可以增强免疫系统，从而预防阿兹海默症。
最后，还有利鲁唑，这是一种透过改变生物途径和降低先前与阿兹海默症等神经退化性疾
病相关的脑化学物质水平来防止神经元死亡的药物。
"Beating dementia will take every avenue of research – from using what we
already know, to discovering new drugs to treat and prevent the condition,"
says Anne Corbett, a dementia researcher at the University of Exeter in the
UK.
"Drug repurposing is a vital part of that mix, helping us turn today's
medicine for one condition, into tomorrow's treatment for another."
As promising as these candidates seem, we can't definitively say these drugs
can prevent or reverse Alzheimer's in human patients yet. The next stage in
the process – comprehensive clinical trials – should tell us much more
about how helpful these treatments can be.
“战胜痴呆症需要从各个研究方向入手—从利用我们已有的知识，到发现治疗和预防这
种疾病的新药，”英国埃克塞特大学的痴呆症研究员安妮·科贝特说。
“药物再利用是其中至关重要的一部分，它帮助我们把今天用于治疗一种疾病的药物，变
成明天治疗另一种疾病的药物。”
尽管这些候选药物看起来很有前景，但我们目前还不能断言它们能够预防或逆转人类患者
的阿兹海默症。下一步—全面的临床试验—应该能让我们更清楚地了解这些疗法的疗
效。
It's clear that there are many different potential contributors to
Alzheimer's, and figuring out how they interlink and affect each other is a
major challenge for researchers.
很明显，阿兹海默症有许多不同的潜在诱因，弄清楚它们如何相互连结和影响是研究人员
面临的重大挑战。
Although much of Alzheimer's pathology is still something of a mystery, what
has been well established is that repurposed drugs can work as treatments for
other conditions – and there are reasons to hope that Alzheimer's disease
might be next.
"It's important to stress that these drugs need further investigation before
we will know whether they can be used to treat or prevent Alzheimer's," says
Corbett.
"We now need to see robust clinical trials to understand their true value and
know for certain if they are effective to treat or prevent Alzheimer's."
The research has been published in Alzheimer's Research & Therapy.
尽管阿兹海默症的病理机制在很大程度上仍然是个谜，但已经证实的是，重新利用的药物
可以用于治疗其他疾病—而且有理由希望阿兹海默症可能是下一个。
科贝特说： “需要强调的是，这些药物还需要进一步研究，我们才能知道它们是否可以
用于治疗或预防阿兹海默症。”
“我们现在需要看到强有力的临床试验，以了解它们的真正价值，并确定它们是否能有效
治疗或预防阿兹海默症。”
这项研究成果已发表在《阿兹海默症研究与治疗》期刊。
5.完整新闻连结 (或短网址)不可用YAHOO、LINE、MSN等转载媒体:
https://reurl.cc/ovzrKj
6.备注:
不只救你小头，现在还能救你大头！